Special and Abbreviated 510(k) Types and MDUFA Fees

1. Key takeaways

510(k) submissions come in three types: Traditional, Special, and Abbreviated. A Special 510(k) applies when a sponsor modifies a device of its own that is already on the market, where the modification affects safety or effectiveness and requires renewed submission. An Abbreviated 510(k) allows the sponsor to rely on FDA guidance documents or Special Controls to demonstrate substantial equivalence. All three types carry the same fee, and the same MDUFA fee schedule applies across the board.

• The FY2026 MDUFA V 510(k) fee is USD 26,067 (small business USD 6,517), and it applies identically to Traditional, Abbreviated, and Special 510(k)s.
• A Special 510(k) is reserved for modifications to a device already cleared under the sponsor’s own 510(k).
• An Abbreviated 510(k) is only viable where applicable FDA guidance or Special Controls already exist for the product code.
• Equal fees do not mean equal preparation cost: Special 510(k)s are usually the least expensive to prepare because existing internal data can be cited extensively.
• Selecting the wrong submission type is a common formal deficiency and forces type changes early in review, extending the timeline.

2. Legal basis

The table below records the authorities defining the three 510(k) types and the FY2026 fee schedule established under MDUFA V, as published in the Federal Register and verified on FDA official pages in 2026.

3. Expert insights

Insight 1: The three 510(k) types carry identical fees but entirely different documentation logic. FDA’s official page states that the application fee applies to Traditional, Abbreviated, and Special 510(k)s. The FY2026 standard fee is USD 26,067, and the small business fee is USD 6,517. Fee parity does not translate into cost parity of preparation. A Special 510(k) is typically the cheapest to prepare because it draws heavily on the sponsor’s own existing cleared device documentation, whereas a Traditional submission for a novel device requires a full independent evidence package. Project budgets should therefore be built around preparation effort, not around the fee schedule alone.

Insight 2: The prerequisite for a Special 510(k) is “our device, our modification.” The Special route applies to modifications of a device already cleared under the sponsor’s own 510(k). If the modification originates from another company’s device, or if the design being submitted belongs to someone else, the Special 510(k) route cannot be used. Verifying this ownership prerequisite at intake prevents the embarrassment and delay of a type correction requested by the reviewing division weeks after submission.

Insight 3: The leverage of an Abbreviated 510(k) lies in guidance or Special Controls that already exist. Where the relevant product code already has an FDA guidance document or established Special Controls, the dossier may cite them directly as conformance evidence, replacing portions of the sponsor’s self-generated data. Where no guidance or Special Controls exist for the product code, the Abbreviated route is simply not available, and the submission must be prepared as Traditional. Checking the product classification database for Special Controls is therefore a mandatory early step.

Insight 4: Mis-selecting the type is one of the most common formal deficiencies. Describing the first market entry of a new device as a Special 510(k), or labeling a device that lacks citable guidance as an Abbreviated 510(k), will both trigger a request to change the submission type early in review, and the change consumes schedule. The type determination should be a documented decision with recorded rationale, made before the dossier is assembled.

A disciplined intake sequence keeps all three streams aligned. Begin with the ownership question that gates the Special route, then check the classification database for citable guidance and Special Controls that would open the Abbreviated route, and only then default to Traditional with the full evidence workload in view. Because the fee is identical regardless of type, the decision should be driven exclusively by eligibility and evidence leverage rather than by any perception that one type reviews faster or more favorably than another. Recording this analysis at intake also gives the later eSTAR completion a fixed reference, reducing the risk that the type field is filled in casually at the end of preparation.

4. Practical recommendations

• Perform the type determination first: modifications to the sponsor’s own cleared device point to Special; citable guidance or Special Controls point to Abbreviated; everything else is Traditional.
• Confirm in the FDA product classification database whether Special Controls have been established for the relevant product code.
• Collect and archive the sponsor’s existing 510(k) dossiers as the evidence foundation for a Special 510(k).
• Determine the 510(k) type option in the eSTAR template at the very start of completion, since the template contains a dedicated field for it.
• Reconfirm eligibility whenever the modification scope changes during development, because a change that alters the affected device profile can shift the appropriate type.

5. Verification checklist

• □ Applicable 510(k) type determined (Traditional / Special / Abbreviated).
• □ If Special, confirmed that the modified device was cleared under the sponsor’s own 510(k).
• □ If Abbreviated, confirmed that citable FDA guidance or Special Controls exist.
• □ Applicable FY2026 fee confirmed (USD 26,067 / small business USD 6,517).
• □ 510(k) type option in eSTAR correctly selected.
• □ Rationale for the type selection recorded and retained.
• □ Preparation budget built around preparation effort and evidence workload, not the fee schedule alone.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, US Agent and local testing support for the United States market. Our team manages FDA establishment registration and listing, 510(k)/De Novo/PMA submissions, and supports post-market reporting obligations. Business enquiries: info@grzanglobal.com